Search Within

Jacqueline Bromberg

  1. "Mark Robson"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (3)
Groups
  1. Breast Medicine Service (9)
  2. Department of Medicine (9)
  3. GSK Faculty (9)
  4. Population Sciences Research Program (9)
  5. Solid Tumor Oncology Division (9)
  6. Survivorship Research (9)

More Groups

People
  1. Mark Robson (9)
  2. Shanu Modi (7)
  3. Andrew Seidman (6)
  4. Chau Dang (6)
  5. Larry Norton (6)
  6. Clifford Hudis (4)

More People

Years
  1. 2024 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2019 (1)
  5. 2013 (1)
  6. 2009 (1)

More Years

Publications
  1. Cancer Research (2)
  2. International Journal of Radiation Oncology, Biology, Physics (2)
  3. Journal of Clinical Oncology (2)
  4. Clinical Cancer Research (1)
  5. Journal of Nuclear Medicine (1)
  6. npj Breast Cancer (1)
Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Clinical Oncology (2)
  3. Elsevier Inc. (2)
  4. Nature Publishing Group (1)
  5. Society of Nuclear Medicine (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • First-in-human evaluation of site-specifically labeled (89)Zr-pertuzumab in patients with HER2-positive breast cancer
    Journal Article

    Yeh, R.; O'Donoghue, J. A.; Jayaprakasam, V. S.; Mauguen, A.; Min, R.; Park, S.; Brockway, J. P.; Bromberg, J. F.; Zhi, W. I.; Robson, M. E.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC)
    Meeting Abstract

    dos Anjos, C. H.; Razavi, P.; Herbert, J.; Colon, J.; Gill, K.; Modi, S.; Bromberg, J.; Dang, C. T.; Liu, D.; Norton, L.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)
    Meeting Abstract

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save